Document Detail


Initial 17beta-estradiol dose for treating vasomotor symptoms.
MedLine Citation:
PMID:  10775738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the efficacy of different doses of 17beta-estradiol (E2) for relief of vasomotor symptoms in menopausal women. METHODS: This was a randomized, double-masked, placebo-controlled, 12-week study in which 333 menopausal women with moderate or severe hot flushes were assigned to treatment with 0.25 mg, 0.5 mg, 1 mg, or 2 mg oral micronized 17beta-E2, or placebo. The number and severity of hot flushes were recorded daily. RESULTS: There was a significant linear correlation between increased dosage of 17beta-E2 and decreased moderate to severe hot flushes per week (P <.001). Rapid reduction in moderate to severe hot flushes was only achieved with 1 and 2 mg, showing a significant difference from placebo at week 4 (P <.05). At week 4, half the women on placebo had reduced moderate to severe hot flushes of at least 52%; the corresponding figures were 56%, 69%, 86%, and 91% for 0.25, 0.5, 1, and 2 mg, respectively. At week 12, all doses except 0.25 mg were significantly better than placebo for reducing moderate to severe hot flushes (P <.001). Although there were no significant differences, twice as many women in the 2-mg group discontinued treatment due to adverse events, compared with the placebo group. CONCLUSION: Oral micronized 17beta-E2 showed a dose-response effect for reducing moderate and severe hot flushes in menopausal women. 17beta-E2 1 mg appeared to be the most useful initial dose.
Authors:
M Notelovitz; J P Lenihan; M McDermott; I J Kerber; N Nanavati; J Arce
Related Documents :
24294188 - Dosimetric evaluation of an ipsilateral intensity modulated radiotherapy beam arrangeme...
9141518 - Mk-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrat...
17479608 - Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal...
24069398 - Cost and effectiveness of decontamination strategies in radiation contaminated areas in...
12507658 - Intrauterine growth retardation and lack of teratogenic effects of prenatal exposure to...
1358918 - Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazos...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  95     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-05-22     Completed Date:  2000-05-22     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  726-31     Citation Subset:  AIM; IM    
Affiliation:
Women's Medical and Diagnostic Center, The Climacteric Clinic, Gainesville, Florida, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Dose-Response Relationship, Drug
Double-Blind Method
Estradiol / administration & dosage*
Estrogen Replacement Therapy*
Female
Hot Flashes / drug therapy*
Humans
Menopause*
Middle Aged
Chemical
Reg. No./Substance:
50-28-2/Estradiol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between body fat distribution and bone mineral density in premenopausal Japanese women.
Next Document:  Estrogen therapy in women undergoing coronary artery bypass grafting: effect on surgical complicatio...